Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

A Randomized, Open Label, Parallel-group, Non-inferiority, Active-controlled, Phase Ⅳ Study to Evaluate the Efficacy and Safety of Teneligliptin Versus Linagliptin in Type 2 Diabetes Mellitus Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03011177

Acronym

TELIUS

Enrollment

168

Registered

2017-01-05

Start date

2017-01-31

Completion date

2018-09-30

Last updated

2019-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes Mellitus

Brief summary

To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 Diabetes Mellitus patients.

Detailed description

A randomized, open label, parallel-group, non-inferiority, active-controlled, phase IV study

Interventions

DRUGTeneligliptin

teneligliptin 20mg qd

DRUGLinagliptin

linagliptin 5mg qd

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are 19 years or older on screening * Patients with type 2 diabetes mellitus * Patients with 7.0% ≤ HbA1c ≤ 11.0% at the screening visit * Patients with Fasting Plasma Glucose \<15mmol/L(270mg/dL) on screening

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
HbA1c	12week

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026